Biofrontera scores FDA filing acceptance for Ameluz PDT in skin cancer breakthrough
If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Subscribe To Our Newsletter & Stay Updated